Akira Mitsuhashi1, Takashi Uehara2, Shinsuke Hanawa2, Makio Shozu2. 1. Department of Reproductive Medicine, Graduate School of Medicine, Chiba University, 1-8-1 Inohana, Chuo-ku, Chiba, 260-8670, Japan. antira@faculty.chiba-u.jp. 2. Department of Reproductive Medicine, Graduate School of Medicine, Chiba University, 1-8-1 Inohana, Chuo-ku, Chiba, 260-8670, Japan.
Abstract
PURPOSE: Obesity and diabetes (DM) are known to increase the risk of endometrial cancer (EC). However, little is known about the prevalence of abnormal glucose metabolism and insulin resistance (IR) in EC patients. We aimed to evaluate the prevalence of abnormal glucose metabolism and IR in EC patients. METHODS: We prospectively enrolled atypical endometrial hyperplasia (AEH) and EC patients who had received planned treatment at Chiba University Hospital, Japan. All patients, except those with a confirmed diagnosis of DM, underwent the 75-g oral glucose tolerance test (OGTT) before treatment. We evaluated the prevalence of obesity, defined as body mass index (BMI) ≥25, IR, abnormal glucose metabolism, and the associations between these three factors and the clinical characteristics of AEH and EC patients. RESULTS: We enrolled 279 patients from April 2009 to March 2015. Of these, 56 had a confirmed diagnosis of DM. Abnormal OGTT results, including impaired fasting glucose (n = 7), impaired glucose tolerance (n = 69), and newly identified DM (n = 33), were noted in 109 patients. Obesity, IR, and abnormal glucose metabolism were observed in 49.8, 51.6, and 59.1% of patients, respectively. Abnormal glucose metabolism was significantly associated with age (P < 0.001), body mass index (P = 0.004), and IR status (P < 0.001) in multivariate analysis. CONCLUSION: Abnormal glucose metabolism, IR, and obesity were highly prevalent in patients with AEH and EC. These results indicate that physicians should consider a patient's metabolic status in the postoperative management of AEH and EC patients.
PURPOSE:Obesity and diabetes (DM) are known to increase the risk of endometrial cancer (EC). However, little is known about the prevalence of abnormal glucose metabolism and insulin resistance (IR) in EC patients. We aimed to evaluate the prevalence of abnormal glucose metabolism and IR in EC patients. METHODS: We prospectively enrolled atypical endometrial hyperplasia (AEH) and EC patients who had received planned treatment at Chiba University Hospital, Japan. All patients, except those with a confirmed diagnosis of DM, underwent the 75-g oral glucose tolerance test (OGTT) before treatment. We evaluated the prevalence of obesity, defined as body mass index (BMI) ≥25, IR, abnormal glucose metabolism, and the associations between these three factors and the clinical characteristics of AEH and EC patients. RESULTS: We enrolled 279 patients from April 2009 to March 2015. Of these, 56 had a confirmed diagnosis of DM. Abnormal OGTT results, including impaired fasting glucose (n = 7), impaired glucose tolerance (n = 69), and newly identified DM (n = 33), were noted in 109 patients. Obesity, IR, and abnormal glucose metabolism were observed in 49.8, 51.6, and 59.1% of patients, respectively. Abnormal glucose metabolism was significantly associated with age (P < 0.001), body mass index (P = 0.004), and IR status (P < 0.001) in multivariate analysis. CONCLUSION:Abnormal glucose metabolism, IR, and obesity were highly prevalent in patients with AEH and EC. These results indicate that physicians should consider a patient's metabolic status in the postoperative management of AEH and EC patients.
Authors: Emma J Crosbie; Marcel Zwahlen; Henry C Kitchener; Matthias Egger; Andrew G Renehan Journal: Cancer Epidemiol Biomarkers Prev Date: 2010-10-28 Impact factor: 4.254
Authors: Jennifer K Burzawa; Kathleen M Schmeler; Pamela T Soliman; Larissa A Meyer; Michael W Bevers; Terri L Pustilnik; Matthew L Anderson; Lois M Ramondetta; Guillermo Tortolero-Luna; Diana L Urbauer; Shine Chang; David M Gershenson; Jubilee Brown; Karen H Lu Journal: Am J Obstet Gynecol Date: 2011-02-16 Impact factor: 8.661
Authors: Marc J Gunter; Donald R Hoover; Herbert Yu; Sylvia Wassertheil-Smoller; Joann E Manson; Jixin Li; Tiffany G Harris; Thomas E Rohan; Xiaonan Xue; Gloria Y F Ho; Mark H Einstein; Robert C Kaplan; Robert D Burk; Judith Wylie-Rosett; Michael N Pollak; Garnet Anderson; Barbara V Howard; Howard D Strickler Journal: Cancer Epidemiol Biomarkers Prev Date: 2008-04 Impact factor: 4.254
Authors: Nicole S Nevadunsky; Anne Van Arsdale; Howard D Strickler; Alyson Moadel; Gurpreet Kaur; Marina Frimer; Erin Conroy; Gary L Goldberg; Mark H Einstein Journal: Gynecol Oncol Date: 2013-11-02 Impact factor: 5.482
Authors: Enrique Fuentes-Mattei; Guermarie Velazquez-Torres; Liem Phan; Fanmao Zhang; Ping-Chieh Chou; Ji-Hyun Shin; Hyun Ho Choi; Jiun-Sheng Chen; Ruiying Zhao; Jian Chen; Chris Gully; Colin Carlock; Yuan Qi; Ya Zhang; Yun Wu; Francisco J Esteva; Yongde Luo; Wallace L McKeehan; Joe Ensor; Gabriel N Hortobagyi; Lajos Pusztai; W Fraser Symmans; Mong-Hong Lee; Sai-Ching Jim Yeung Journal: J Natl Cancer Inst Date: 2014-06-23 Impact factor: 13.506
Authors: Christine M Friedenreich; Annie R Langley; Thomas P Speidel; David C W Lau; Kerry S Courneya; Ilona Csizmadi; Anthony M Magliocco; Yutaka Yasui; Linda S Cook Journal: Endocr Relat Cancer Date: 2012-11-09 Impact factor: 5.678
Authors: V N Sivalingam; S Kitson; R McVey; C Roberts; P Pemberton; K Gilmour; S Ali; A G Renehan; H C Kitchener; E J Crosbie Journal: Br J Cancer Date: 2016-01-21 Impact factor: 7.640
Authors: Sarah J Kitson; Jennifer Lindsay; Vanitha N Sivalingam; Mark Lunt; Neil A J Ryan; Richard J Edmondson; Martin K Rutter; Emma J Crosbie Journal: Gynecol Oncol Date: 2017-11-24 Impact factor: 5.482